Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Immune cells track hard-to-target brain tumours

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature 565, 170-171 (2019)



  1. 1.

    Yarchoan, M. et al. N. Engl. J. Med. 377, 2500–2501 (2017).

    PubMed  Article  Google Scholar 

  2. 2.

    Wolchok, J. D. et al. N. Engl. J. Med. 377, 1345–1356 (2017).

    PubMed  Article  Google Scholar 

  3. 3.

    Yarchoan, M. et al. Nature Rev. Cancer 17, 209–222 (2017).

    PubMed  Article  Google Scholar 

  4. 4.

    Keskin, D. B. et al. Nature 565, 234–239 (2019).

    Article  Google Scholar 

  5. 5.

    Hilf, N. et al. Nature 565, 240–245 (2019).

    Article  Google Scholar 

  6. 6.

    Ott, P. A. et al. Nature 547, 217–221 (2017).

    PubMed  Article  Google Scholar 

  7. 7.

    Sahin, U. et al. Nature 547, 222–226 (2017).

    PubMed  Article  Google Scholar 

  8. 8.

    Kinkead, H. L. et al. JCI Insight 3, e122857 (2018).

    Article  Google Scholar 

  9. 9.

    Friaetta, J. A. et al. Nature Med. 24, 563–571 (2018).

    PubMed  Article  Google Scholar 

  10. 10.

    Popovic, A. et al. J. Clin. Invest. 128, 3209–3318 (2018).

    PubMed  Article  Google Scholar 

Download references

Competing Interests

E.M.J. serves on the scientific advisory boards of four immunotherapy companies: CSTONE, Genocea, Adaptive Biotech and DragonFly. E.M.J. receives grant money from Aduro Biotech, Hertix and Bristol-Myers Squibb and has the potential to receive royalties on a vaccine licensed to Aduro Biotech. Also, E.M.J. is the president of the American Association for Cancer Research and serves as the chairperson of the National Cancer Advisory Board.


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links